Your genes may determine if the Morning-After pill works

NCT ID NCT05674513

Recruiting now Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates whether genetic differences affect how the body processes the emergency contraceptive ulipristal acetate, potentially explaining why some women experience contraceptive failure. Researchers will compare women with and without active CYP3A5 genes, measuring drug levels and ovulation timing after a single dose. The goal is to understand if inherited traits influence emergency contraception effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ulipristal acetate
What this could lead to: If successful, this could help identify women at higher risk of emergency contraceptive failure and guide more personalized contraceptive choices.
What could go wrong: This is a small Phase 4 study focused on biological mechanisms, not a large efficacy trial. Results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTIVE USAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Contraception Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTIVE USAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

OHSU
RECRUITING

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.